Does IBRITUMOMAB TIUXETAN Cause Progressive multifocal leukoencephalopathy? 62 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 62 reports of Progressive multifocal leukoencephalopathy have been filed in association with IBRITUMOMAB TIUXETAN (Zevalin). This represents 10.3% of all adverse event reports for IBRITUMOMAB TIUXETAN.
62
Reports of Progressive multifocal leukoencephalopathy with IBRITUMOMAB TIUXETAN
10.3%
of all IBRITUMOMAB TIUXETAN reports
47
Deaths
24
Hospitalizations
How Dangerous Is Progressive multifocal leukoencephalopathy From IBRITUMOMAB TIUXETAN?
Of the 62 reports, 47 (75.8%) resulted in death, 24 (38.7%) required hospitalization, and 3 (4.8%) were considered life-threatening.
Is Progressive multifocal leukoencephalopathy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IBRITUMOMAB TIUXETAN. However, 62 reports have been filed with the FAERS database.
What Other Side Effects Does IBRITUMOMAB TIUXETAN Cause?
Sepsis (123)
Meningitis tuberculous (111)
Off label use (83)
Thrombocytopenia (75)
Myelodysplastic syndrome (72)
Mucosal inflammation (56)
Neutropenia (55)
Anaemia (53)
Febrile neutropenia (49)
Acute myeloid leukaemia (44)
What Other Drugs Cause Progressive multifocal leukoencephalopathy?
NATALIZUMAB (1,668)
RITUXIMAB (1,647)
CYCLOPHOSPHAMIDE (782)
PREDNISONE (606)
PREDNISOLONE (439)
TACROLIMUS (438)
METHOTREXATE (428)
DOXORUBICIN (421)
MYCOPHENOLATE MOFETIL (414)
VINCRISTINE (376)
Which IBRITUMOMAB TIUXETAN Alternatives Have Lower Progressive multifocal leukoencephalopathy Risk?
IBRITUMOMAB TIUXETAN vs IBRUTINIB
IBRITUMOMAB TIUXETAN vs IBUPROFEN
IBRITUMOMAB TIUXETAN vs IBUPROFEN LYSINE
IBRITUMOMAB TIUXETAN vs IBUPROFEN UNKNOWN PRODUCT
IBRITUMOMAB TIUXETAN vs IBUPROFEN\IBUPROFEN